- Home
- RTSN vs RNXT Comparison
RTSN vs RNXT Comparison
Compare RTSN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$12.00
N/A
Current Price
$1.22
Company Overview
Basic Information| Metric | RTSN | RNXT |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.2M | 79.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RTSN | RNXT |
|---|---|---|
| Price | $12.00 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $51.67 | $7.25 |
| AVG Volume (30 Days) | 108.1K | ★ 385.0K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $243.48 |
| Revenue Next Year | N/A | $196.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $10.31 | $0.70 |
| 52 Week High | $18.64 | $2.59 |
Technical Indicators
Market Signals| Indicator | RTSN | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 43.28 |
| Support Level | $10.58 | $0.83 |
| Resistance Level | $12.93 | $1.30 |
| Average True Range (ATR) | 1.50 | 0.16 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 30.50 | 49.25 |
Price Performance
Historical Comparison RTSN
RNXT
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.